Try our mobile app

BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA

Published: 2024-01-03 13:00:00 ET
<<<  go to BMRN company page

SAN RAFAEL, Calif., Jan. 3, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 42nd Annual J.P. Morgan Conference on Monday January 8, 2024, at 10:30 am PT / 1:30 pm ET, in San Francisco, California. 

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

An audio webcast of the presentations will be available live. You can access the webcasts at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

About BioMarinFounded in 1997, BioMarinis a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of the genetic conditions. BioMarin'sunparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.

Contacts:

InvestorsTraci McCartyBioMarin Pharmaceutical Inc.(415) 455-7558

MediaMarni KottleBioMarin Pharmaceutical Inc.(650) 374-2803

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-on-monday-january-8-at-1030-am-pt--130-pm-et-in-san-francisco-ca-302025143.html

SOURCE BioMarin Pharmaceutical Inc.